Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.
Respiratory Virus Season 2024-2025: Expert Insights to Help Primary Care Prepare
Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data
CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.
Early Identification, Treatment of COPD Reduces Exacerbations, Health Care Burden
CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.